Updated phase 2 data showed a 60% ORR and 86% CNS ORR with frontline silevertinib in non-classical EGFR-mutant NSCLC; FDA discussion supported a phase 3 trial in 2027.
|Videos|May 26, 2017
NSCLC with Multiple Sites of Metastasis and No Driver Mutation
NSCLC with Multiple Sites of Metastasis and No Driver Mutation
Advertisement
- A 64-yr old gentleman presented with headache, impaired vision in left eye, and intermittent confusion that had begun a few weeks ago
- He is a current non-smoker with a 30-pack-year history
- Past medical history: hypertension diagnosed 3 years ago, well-controlled on losartan
- His cardiac workup is negative
- His PS by ECOG assessment is 1
- Head computed tomography demonstrated a mass (1.0 cm) in left occipital lobe with associated edema
- Full body CT scan revealed a left lower lobe lung mass (2.2 cm), and ipsilateral mediastinal lymphadnopathy
- Whole body 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) scan revealed increased FDG uptake in the primary left lower lobe lung mass, mediastinum, and several bony sites
- Core biopsy of the lung mass was performed and indicated
- A histopathological diagnosis of adenocarcinoma (staining for TTF-1 was positive)
- Genetic testing was negative for known driver mutations
- PD-L1 testing by IHC showed expression in 15% of cells
- Brain MRI revealed 2 additional 8 mm lesions in the left frontal and right temporal lobes
- He was diagnosed with stage IV NSCLC adenocarcinoma
- He was treated with stereotactic radiosurgery (SRS) for brain metastases
- Two weeks following SRS
- A follow up MRI scan showed no evidence of new brain metastases
- CT scan showed:
- 4 smaller nodules in the left upper lobe
- The left lower lobe lung mass increased in size to 3.3 cm
- Ipsilateral mediastinal lymph node swelling
- The patient was started on therapy with carboplatin/paclitaxel and bevacizumab
Advertisement
Related to this article
FDA issues a not approvable letter for Novocure’s Optune Mya in NSCLC brain metastases, citing uncertain clinical benefit. No safety concerns were raised.
Imneskibart showed promising outcomes and tolerability in patients who had previously received immune checkpoint inhibition for either melanoma or lung adenocarcinoma.
In KEYNOTE-867, adding pembrolizumab to radiotherapy did not extend event-free survival in inoperable early-stage NSCLC and raised toxicity; the phase 3 trial was stopped for futility in 2024.
Advertisement
Advertisement
Trending on Targeted Onc
1
FDA Approves OncoMate MSI Dx For Pembrolizumab in MSI-H Tumors
2
Novocure’s Optune Mya Gets FDA Not Approvable Letter
3
Anbal-Cel Demonstrates Clinical Activity in Relapsed LBCL
4
In Phase 3, Ponatinib/Blinatumomab Improves EFS in Ph+ ALL
5